Clinical trial
STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With…
NCT00006343 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00006343 |
|---|---|
| Title | STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia |
| Official title | A Phase III Study of STI571 Versus Interferon-a (IFN-a) Combined With Cytarabine (Ara-C) in Patients With Newly Diagnosed Previously Untreated Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) |
| Lead sponsor | Novartis, Industry |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Drug |
| Interventions | recombinant interferon alfa, cytarabine, imatinib mesylate |
| Start date | Jun 1, 2000 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | May 26, 2004 |
| Last update posted | Jan 3, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: